Sirnaomics Ltd

Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company that discovers and develops drugs for medical needs in the People's Republic of China. Its therapeutic products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Lead drug candidates include STP705 for non-melanoma skin cancer and focal fat reduction, STP369 for head and neck cancer, and STP707 and STP355 for solid tumors. The company is also developing STP122G for coagulation disorders, STP125G for hypertriglyceridemia, and STP144G, STP145G, and STP146G for complement diseases, as well as STP247G for complement diseases, STP152G for amyloidosis, STP705 for fat reduction, STP237G and STP251G for hypertension in combination with familial hypertriglyceridemia, and STP136G for hypertension. Incorporated in 2007, it is headquartered in Germantown, Maryland.